


Srdečně Vás zveme na přednášku na téma:
Advancements in Transmyocardial Revascularization & Synergism with Stem Cell Therapy Workshop
(Pořádá společnost Hospimed s.r.o.)

Přednáška se bude konat v těchto termínech

Datum	12.4.2007 – 8:00	13.4.2007 - 8:30	13.4.2007 – 14:00
Místo konání	FN Plzeň	FN Brno	IKEM Praha

Přednášející:

***Dr. Keith Allen,
Cardio-thoracic Surgeon,
Indianapolis, Indiana, USA***



Abstract přednášky:

Many patients with chronic angina related to coronary artery disease respond to medical management or can be completely revascularized using percutaneous coronary interventions or coronary artery bypass grafting (CABG). Cardiac surgeons, however, are increasingly faced with a more complex patient who has developed a pattern of diffuse coronary artery disease and who cannot be completely revascularized by CABG alone (Figure 1). Incomplete revascularization with CABG occurs in 10-25% of patients and is a risk factor for both early and late death as well as late adverse events such as recurrent chest pain. Transmyocardial laser revascularization (TMR) is an approved surgical option for patients with debilitating angina due to diffuse coronary artery disease which makes complete revascularization using CABG alone unlikely. Based on the results of seven randomized trials the American Heart Association/American College of Cardiology (2002), the Society of Thoracic Surgeons (2004) and the International Society for Minimally Invasive Cardiothoracic Surgery (2006) have established national practice guidelines recommending TMR as sole therapy or as an adjunct to CABG in this difficult patient group.



The mechanism for TMR's benefit is likely multifactorial but the laser channel creates a localized area of injured heart muscle cells which during their repair stimulates new blood vessel growth or angiogenesis. It has been demonstrated that injection of biologics such as stem cells or growth factors at the time of creating the laser channel enhances angiogenesis beyond the affect that either TMR or stem cells would have by themselves. It is hypothesized that the inflammation caused by the TMR channel provides a 'fertile' area for enhanced stem cell uptake and angiogenesis.



HOSPIMED, spol. s r.o.

Malešická 2251/51

130 00 Praha 3

The use of stem cells in surgery, however, has been hampered by ethical concerns as well the inability to efficiently culture or isolate them outside the laboratory. The approval by the FDA of an autologous bone marrow stem cell isolator (HARVEST, Inc, Boston, MA) has removed these barriers. The bone marrow is collected in the operating room at the time of surgery and using the HARVEST system it is separated into its different parts in a process that is 'point of care' and takes only 15-20 minutes. The patients own sterilely concentrated stem cells can then be utilized in an efficient and timely manner during surgery. Stem cells concentrated using this system is already effectively and safely utilized clinically in orthopedic surgery with clinical trials underway to treat peripheral vascular disease. The ability to efficiently concentrate a patient's own bone marrow derived stem cells now makes clinical application possible.

The treatment of diffuse coronary artery disease remains a challenging endeavor even in the best of hands. CABG in conjunction with TMR has demonstrated superior efficacy in this patient population. The addition of autologous stem therapy to this regimen holds potential for enhanced angiogenesis thereby maximizing treatment effect in this difficult group of patients.

Dr. Keith Allen bio:

Keith B. Allen, MD is an attending cardiothoracic surgeon at St. Vincent Medical Center in Indianapolis. He is a member of the American Association of Thoracic Surgeons and the Society of Thoracic Surgeons. Dr. Allen is a leading authority on the research and clinical application of Transmyocardial Revascularization (TMR). He was the principal investigator of pivotal randomized clinical trials of TMR versus Medical Management and TMR plus CABG versus CABG Alone using the Ho: Yag laser technology. He also participated in the single arm trial assessing the safety and efficacy of TMR in patients with unstable angina. Dr. Allen has performed over 700 TMR procedures and has formally trained over 800 cardiothoracic surgeons on this therapy.

Dr. Allen has presented the results of the randomized controlled clinical trials of TMR with the Ho: YAG laser technology at the scientific sessions of the annual meetings of the American Association of Thoracic Surgeons, the Society of Thoracic Surgeons, the American College of Cardiology and the American Heart Association. He has authored two book chapters and eight peer-reviewed articles published on TMR, including articles in New England Journal of Medicine, Journal of Thoracic and Cardiovascular Surgery, Annals of Thoracic Surgery and Circulation. He is also a contributing author on the STS Practice Guidelines for TMR (Annals of Thoracic Surgery).



HOSPIMED, spol. s r.o.
Malešická 2251/51
130 00 Praha 3



Prosím vyplňte následující formulář a odešlete zpět

Registrační formulář

Kontaktní osoba:
Michal Podzimek
Email: michal.podzimek@hospimed.cz
Tel: 724 329 430

Jméno, příjmení:

Pracoviště:

E-mail:

V tabulce prosím zaškrtněte preferovaný termín přednášky

Datum	12.4.2007 – 8:00	13.4.2007 - 8:30	13.4.2007 – 14:00
Místo konání	FN Plzeň Kardiochirurgické odd. Seminární místnost	FN Brno Interní kardiologická klinika seminární místnost (učebna) - 13. podlaží	IKEM Praha Kongresový sál
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>